CHRYSALIS-2: A phase 1/1b study of lazertinib as monotherapy and in combination with amivantamab in patients with EGFR-mutant NSCLC.

Catherine A. Shu,Koichi Goto,Byoung Chul Cho,Frank Griesinger,James Chih-Hsin Yang,Enriqueta Felip,John Xie,Jun Chen,Janine Mahoney,Meena Thayu,Roland Elmar Knoblauch,Leonardo Trani,Joshua Bauml

CHRYSALIS-2: A phase 1/1b study of lazertinib as monotherapy and in combination with amivantamab in patients with EGFR-mutant NSCLC.

2021

Catherine A. Shu
Koichi Goto
Byoung Chul Cho
Frank Griesinger
James Chih-Hsin Yang
Enriqueta Felip
John Xie
Jun Chen
Janine Mahoney
Meena Thayu
Roland Elmar Knoblauch
Leonardo Trani
Joshua Bauml

TPS9132Background: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have improved clinical outcomes for patients with EGFR mutant (EGFRm) non-small cell lung cancer (NSCLC)...

Keywords:

Medicine
Epidermal growth factor receptor
non small cell
Mutant
in patient
Cancer research
Tyrosine kinase

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations